During the recent session, Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s traded shares were 2.31 million, with the beta value of the company hitting 1.50. At the last check today, the stock’s price was $15.08, reflecting an intraday gain of 16.81% or $2.17. The 52-week high for the AVDL share is $19.09, that puts it down -26.59 from that peak though still a striking 35.74% gain since the share price plummeted to a 52-week low of $9.69. The company’s market capitalization is $1.45B, and the average intraday trading volume over the past 10 days was 0.55 million shares, and the average trade volume was 876.84K shares over the past three months.
Avadel Pharmaceuticals plc (AVDL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AVDL has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 8 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.05.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Avadel Pharmaceuticals plc (NASDAQ:AVDL) trade information
Avadel Pharmaceuticals plc (AVDL) registered a 16.81% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 16.81% in intraday trading to $15.08, hitting a weekly high. The stock’s 5-day price performance is 16.00%, and it has moved by 15.47% in 30 days. Based on these gigs, the overall price performance for the year is 52.94%. The short interest in Avadel Pharmaceuticals plc (NASDAQ:AVDL) is 10.19 million shares and it means that shorts have 12.45 day(s) to cover.
The consensus price target of analysts on Wall Street is $12, which implies a decrease of -25.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9 and $30 respectively. As a result, AVDL is trading at a discount of -98.94% off the target high and 40.32% off the low.
Avadel Pharmaceuticals plc (AVDL) estimates and forecasts
Statistics show that Avadel Pharmaceuticals plc has outperformed its competitors in share price, compared to the industry in which it operates. Avadel Pharmaceuticals plc (AVDL) shares have gone down -17.60% during the last six months, with a year-to-date growth rate more than the industry average at 75.00% against 17.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 87.80% this quarter and then jump 96.60% in the quarter after that. In the rating firms’ projections, revenue will increase 520.80% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 48.61M as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 56.18M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 7.01M and 19.45M respectively. In this case, analysts expect current quarter sales to grow by 593.00% and then jump by 188.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 4.78%. While earnings are projected to return 74.19% in 2024, the next five years will return 15.00% per annum.
AVDL Dividends
Avadel Pharmaceuticals plc is due to release its next quarterly earnings on 2024-Nov-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s Major holders
Avadel Pharmaceuticals plc insiders own 4.77% of total outstanding shares while institutional holders control 80.00%, with the float percentage being 84.01%. VIVO CAPITAL, LLC is the largest shareholder of the company, while 214.0 institutions own stock in it. As of 2024-06-30, the company held over 3.97 million shares (or 4.332% of all shares), a total value of $55.85 million in shares.
The next largest institutional holding, with 1.19 million shares, is of TRI LOCUM PARTNERS LP’s that is approximately 1.2973% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $16.72 million.
